ArticleMultiple sclerosis and related disorders2022

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.

David Baker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.